[go: up one dir, main page]

MX2025004001A - Composicion farmaceutica para la prevencion o el tratamiento de nefropatia y/o diabetes mellitus, que comprende enavogliflozina - Google Patents

Composicion farmaceutica para la prevencion o el tratamiento de nefropatia y/o diabetes mellitus, que comprende enavogliflozina

Info

Publication number
MX2025004001A
MX2025004001A MX2025004001A MX2025004001A MX2025004001A MX 2025004001 A MX2025004001 A MX 2025004001A MX 2025004001 A MX2025004001 A MX 2025004001A MX 2025004001 A MX2025004001 A MX 2025004001A MX 2025004001 A MX2025004001 A MX 2025004001A
Authority
MX
Mexico
Prior art keywords
enavogliflozin
prevention
treatment
pharmaceutical composition
nephropathy
Prior art date
Application number
MX2025004001A
Other languages
English (en)
Inventor
Hwa Rang Song
Young Hee Kim
Jae Jin Nah
Wan Huh
Seung Ah Cho
Mi Hee Park
Si Eun Lee
Su Young Kim
Bo Young Cho
Jae Min Cho
Seong In Cho
Ji-Soo Choi
hye young Ji
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2025004001A publication Critical patent/MX2025004001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende enavogliflozina como principio activo para la prevención o el tratamiento de diabetes y/o enfermedades renales en pacientes que tienen o están en riesgo de diabetes y/o enfermedades renales.
MX2025004001A 2022-10-05 2025-04-03 Composicion farmaceutica para la prevencion o el tratamiento de nefropatia y/o diabetes mellitus, que comprende enavogliflozina MX2025004001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220127340 2022-10-05
PCT/KR2023/015349 WO2024076177A1 (ko) 2022-10-05 2023-10-05 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
MX2025004001A true MX2025004001A (es) 2025-05-02

Family

ID=90608375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025004001A MX2025004001A (es) 2022-10-05 2025-04-03 Composicion farmaceutica para la prevencion o el tratamiento de nefropatia y/o diabetes mellitus, que comprende enavogliflozina

Country Status (10)

Country Link
EP (1) EP4599828A1 (es)
JP (1) JP2025533903A (es)
KR (1) KR20240047952A (es)
CN (1) CN119997945A (es)
AU (1) AU2023355275A1 (es)
CL (1) CL2025001006A1 (es)
MA (1) MA71282A1 (es)
MX (1) MX2025004001A (es)
WO (1) WO2024076177A1 (es)
ZA (1) ZA202502846B (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090603A1 (es) * 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EA201300522A1 (ru) * 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
CN103596564B (zh) 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
KR20150130177A (ko) * 2014-05-13 2015-11-23 한미약품 주식회사 Sglt 저해제로서 2,3-다이하이드로벤조퓨란 유도체 및 이를 포함하는 약학적 조성물
KR101832982B1 (ko) * 2014-10-13 2018-02-27 주식회사 엘지화학 제미글립틴 및 제미글립틴 활성 대사체를 이용한 혈관 합병증의 예방 및 치료
NZ749398A (en) 2016-06-17 2020-01-31 Green Cross Corp Method for producing diphenylmethane derivative
CN113272013A (zh) * 2019-12-17 2021-08-17 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
CN115023318B (zh) 2020-01-29 2023-11-10 阿特拉斯·科普柯工业技术公司 适于在扭矩以脉冲形式传递的情况下执行紧固操作的电动工具
MX2022012557A (es) * 2020-04-10 2023-01-19 Chinook Therapeutics Inc Metodos de tratamiento de la enfermedad renal diabetica.

Also Published As

Publication number Publication date
KR20240047952A (ko) 2024-04-12
CN119997945A (zh) 2025-05-13
CL2025001006A1 (es) 2025-05-30
ZA202502846B (en) 2025-12-17
MA71282A1 (fr) 2025-12-31
EP4599828A1 (en) 2025-08-13
AU2023355275A1 (en) 2025-04-24
WO2024076177A1 (ko) 2024-04-11
JP2025533903A (ja) 2025-10-09

Similar Documents

Publication Publication Date Title
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
MX2012007410A (es) Compuestos antivirales novedosos.
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
ZA202310748B (en) Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
WO2007144080A3 (de) Antidepressiva-kombinations-wafer
CA3156680A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
TW200616644A (en) Medicine for prevention or treatment of diabetes
EA200600176A1 (ru) Фармацевтические композиции, содержащие аскорбиновую кислоту для лечения грибковых суперинфекций и грибковых рецидивов
ZA202502846B (en) Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
WO2021022058A3 (en) Antiarrhythmic formulation
WO2009035253A3 (en) Novel use of scoparone
ZA202400915B (en) Pharmaceutical composition and use thereof
ZA202311241B (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
Mp et al. Blood pressure control of fixed dose, perindopril/amlodipine combination treatment in hypertensive patients uncontrolled on monotherapy or on two drug combination therapy: PP. 5.167
DE502004011874D1 (de) Flupirtine-präparat zur behandlung von neurodegeneetes mellitus
IS8373A (is) Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn
TH2101002485A (th) องค์ประกอบทางเภสัชกรรมสำหรับรักษาโรคเบาหวานชนิดที่ 2
TW200608965A (en) Medicine for prevention or treatment of diabetes